Compounds > angiotensin ii
Page last updated: 2024-08-22

angiotensin ii and vinpocetine

angiotensin ii has been researched along with vinpocetine in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beavo, JA; Berk, BC; Kim, D; Munzel, T; Pi, X; Rybalkin, SD; Wang, Y; Yan, C; Zhang, C1
Carneiro, FS; Giachini, FR; Lima, VV; Tostes, RC; Webb, RC1
Grave, K; Hering, L; Hoch, H; Mergia, E; Potthoff, SA; Rump, LC; Sivritas, SH; Stegbauer, J; Thieme, M; Yang, G1
Li, JD; Wu, MP; Xu, X; Yan, C; Zhang, YS; Zhou, Q1

Other Studies

4 other study(ies) available for angiotensin ii and vinpocetine

ArticleYear
Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance.
    Circulation, 2001, Nov-06, Volume: 104, Issue:19

    Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Angiotensin II; Animals; Aorta; Atrial Natriuretic Factor; Cells, Cultured; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Tolerance; Enzyme Induction; In Vitro Techniques; Isoenzymes; Male; Muscle, Smooth, Vascular; Nitric Oxide Donors; Nitroglycerin; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats; Rats, Sprague-Dawley; RNA, Messenger; Up-Regulation; Vasodilator Agents; Vinca Alkaloids

2001
Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1.
    Hypertension (Dallas, Tex. : 1979), 2011, Volume: 57, Issue:3

    Topics: Analysis of Variance; Angiotensin II; Animals; Antihypertensive Agents; Arteries; Blood Pressure; Blotting, Western; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Dose-Response Relationship, Drug; Hypertension; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Vasoconstriction; Vinca Alkaloids

2011
Phosphodiesterase 5 inhibition ameliorates angiotensin II-dependent hypertension and renal vascular dysfunction.
    American journal of physiology. Renal physiology, 2017, 03-01, Volume: 312, Issue:3

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cyclic GMP; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension; Male; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphodiesterase 5 Inhibitors; Renal Artery; Renal Circulation; Sildenafil Citrate; Vasodilation; Vasodilator Agents; Vinca Alkaloids

2017
Vinpocetine Attenuates Pathological Cardiac Remodeling by Inhibiting Cardiac Hypertrophy and Fibrosis.
    Cardiovascular drugs and therapy, 2017, Volume: 31, Issue:2

    Topics: Angiotensin II; Animals; Cardiomegaly; Cardiomyopathies; Cell Proliferation; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 1; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Matrix; Extracellular Matrix Proteins; Fibroblasts; Fibrosis; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphodiesterase Inhibitors; Signal Transduction; Ventricular Remodeling; Vinca Alkaloids

2017